Citigroup Reduces Stake in Glaukos Corporation

Institutional investor sells over 34,000 shares of medical device company

Mar. 9, 2026 at 7:38am

Got story updates? Submit your updates here. ›

Citigroup Inc. has reduced its holdings in Glaukos Corporation (NYSE:GKOS), a medical instruments supplier, by 61.3% in the third quarter. The firm sold 34,689 shares during the period, leaving it with 21,912 shares worth $1.787 million as of its most recent SEC filing.

Why it matters

Citigroup's move to significantly trim its position in Glaukos reflects broader trends in the investment community around the medical device company. The stock has seen increased institutional interest and volatility in recent quarters as Glaukos navigates the competitive landscape for its innovative glaucoma treatment products.

The details

According to the SEC filing, Citigroup sold 34,689 shares of Glaukos in the third quarter, reducing its total holdings to 21,912 shares. This represented a 61.3% decrease in Citigroup's position in the company. Glaukos is a medical device maker focused on developing micro-invasive glaucoma surgery (MIGS) products, including its flagship iStent trabecular micro-bypass stent.

  • Citigroup reduced its Glaukos holdings in the third quarter of the year.

The players

Citigroup Inc.

A multinational investment bank and financial services corporation.

Glaukos Corporation

A medical technology company specializing in the development and commercialization of innovative therapies for the treatment of glaucoma and other chronic eye diseases.

Got photos? Submit your photos here. ›

The takeaway

Citigroup's reduced stake in Glaukos reflects the volatility and uncertainty surrounding the medical device company as it competes in the MIGS market. This move highlights the need for Glaukos to continue innovating and executing on its growth strategy to maintain investor confidence.